Framingham Online News

Genzyme to Invest $80M in Framingham Plant

October 16, 2013 (8:07 am EST)
Filed under: Business by News Staff
Genzyme (logo)

Genzyme currently has three facilities in Framingham, the Genzyme Science Center at 49 New York Ave, and offices at 200 Crossing Blvd and 11 Pleasant Street.

FRAMINGHAM, MA - This week, Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced that it is investing $80 million to build a new downstream processing facility for Fabrazyme® (agalsidase beta).

The new plant, which will be located adjacent to the new Fabrazyme cell culture manufacturing site in Framingham, Massachusetts, will significantly expand purification capacity to support anticipated growth in global demand over the coming years.

“As we continue to meet the global demands for Fabrazyme and build inventory, our focus also remains on the future needs of the global Fabry community,” said Genzyme President and CEO, David Meeker, M.D. “Following last year’s regulatory approvals of our manufacturing facility in Framingham and ...[read more]